Charcot-Marie-Tooth Disease Market, by Disease Type (CMT 1, CMT 2, CMT 3, and Others), by Drug Type (Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics and Pipeline Drug), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Oct 2021

Code : CMI4698

Pages :189

Formats :

Excel and PDF

Industry : Pharmaceutical

Charcot-Marie-Tooth Disease MarketSize and Trends

The global charcot-marie-tooth disease market is estimated to be valued at US$ 793.9 Million in 2021 and is expected to increase to US$ 3,459.1 Million by 2028, witnessing a CAGR of 23.4% over the forecast period (2021-2028).

Figure 1. Global Charcot-Marie-Tooth Disease Market Value (US$ Mn) & Y-o-Y Growth (%)

Increasing prevalence of charcot-marie-tooth disease is expected to drive the growth of the global charcot-marie-tooth disease market.

Increasing prevalence of charcot-marie-tooth disease is expected to drive the growth of the global charcot-marie-tooth disease market. For instance, according to the information provided by MedlinePlus in September 2020, charcot-marie-tooth disease is the most common genetic disease, involving peripheral nerves and affecting the population. One in every 3,300 people in the world is affected by the disease. Furthermore, according to the same source, 70% to 80% of CMT1 patients have mutations that affect the PMP22 gene. Most of these situations occur when there are extra copies of the gene due to a small duplication of genetic material on chromosome 17. Another 10% to 12% of CMT1 patients have mutations in the MPZ gene. The most common cause of CMT2 is a mutation in the MFN2 gene, which accounts for about 20% of cases of total CMT cases. Approximately 90% of CMTX patients have mutations in the GJB1 gene.

Global Charcot-Marie-Tooth Disease Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sector, which is majorly impacted by the COVID-19 pandemic.

The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments.